Ouro Medicines Announces Expansion of Clinical Development for OM336 in Sjögren's Disease ...

Ouro Medicines, a biotechnology company developing immune reset therapeutics for people living with chronic, immune-mediated ...
Morningstar

Aera Therapeutics Presents Preclinical Data and Announces Nomination of First Development ...

Aera Therapeutics Presents Preclinical Data and Announces Nomination of First Development Candidate, AERA-109, a Targeted In Vivo CAR-T Therapy for B Cell-mediated Autoimmune Diseases Preclinical data ...